BRIDGEWATER, NJ--(Marketwire - March 13, 2012) - EBI (NASDAQ: ENL) invites decision-makers from far and wide to join keynote speakers Freda Lewis Hall, M.D., Executive Vice President & Chief Medical Officer of Pfizer, and Jay Galeota, President, Hospital & Specialty Care of Merck and Co., at the 9th Annual 2012 PSO conference at the Grand Hyatt New York from April 11th to the 13th, where you can NETWORK with the world’s leading executives, PARTNER with hand-selected presenting companies, and LEARN from top dealmaking and finance strategists.
The PSO Conference is an in-depth analysis on the top issues affecting the industry offering attendees a personal, hands-on, interactive setting with comprehensive on-stage interviews, engaging panels, one-on-one partnering meetings, and company presentations by carefully selected biotech companies. Focusing on Biopharma Strategic Dealmaking, PSO promises many notable speakers, including but not limited to Iain Dukes, Vice President of External Research and Development at Amgen, Ron Laufer, Senior Managing Director of MedImmune Ventures at AstraZeneca, as well as Dr. Jeffrey Jonas, SVP of Research & Development of Specialty Pharmaceuticals & Regenerative Medicine at Shire plc.
Every year, senior level business development and licensing executives from small to large pharmaceutical and biotechnology companies attend PSO to meet their current and potential strategic partners, as well as hear from industry stakeholders and key thought leaders, who’ll share practical advice and strategies on how to structure successful deals. PSO 2012 will facilitate thought-provoking discussions by experienced industry leaders who want to learn the deal values and deal specifics that let you calibrate deal-making metrics.
Walk away with practical, real-life lessons from some of the most experienced dealmakers in the industry on how they evaluate opportunities and risk for their line of business as well as their own professional growth. This year’s agenda offers a wide array of exciting topics including a new panel titled, Executive Compensation: Are Dealmakers Paid Enough? Other new and noteworthy topics also include:
- Debate: The Runners and Riders in the Race for the Next Blockbuster
- More from Less: Optimizing the R&D Budget
- The Next Big Opportunity: Picking the Lottery Numbers
- Creative Deal Structures: 2010/2011 Winners
- Outlicensing: Stepping Stone or Exit?
Join us at PSO and take full advantage of this opportunity, to not only learn the latest winning strategies from top dealmakers in the industry, but also to find the strategic partners you need to fuel your own success! To register, for more information, or to hear what past attendees are saying about PSO, visit www.psoconference.com/content/Main.aspx.
About Elsevier Business Intelligence
Elsevier Business Intelligence (EBI) is global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, EBI places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. EBI (www.elsevierbi.com) has offices in the U.S. in Bridgewater, NJ; Norwalk, CT; Rockville, MD; and Irvine, CA.
Heej Ko
203-840-6269
Email Contact
